Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

References

• Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990;82(19):1539–1545. doi:10.1093/jnci/82.19.15392402015
   PubMed Web of Science ®Google Scholar
• Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast. 2014;23(5):526–537. doi:10.1016/j.breast.2014.06.00425034931
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 2001;2001(30):96–102. doi:10.1093/oxfordjournals.jncimonographs.a003469
   Google Scholar
• van der Hage JA, van de Velde CJH, Julien J-P, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19(22):4224–4237. doi:10.1200/JCO.2001.19.22.422411709566
   PubMed Web of Science ®Google Scholar
• Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007;9(5):110. doi:10.1186/bcr175517888189
   PubMed Web of Science ®Google Scholar
• Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11(6):574–589. doi:10.1634/theoncologist.11-6-57416794237
   PubMed Web of Science ®Google Scholar
• Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23(4):1104–1110. doi:10.1245/s10434-015-4934-026511266
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159. doi:10.1056/NEJMoa161264528564564
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa181401730516102
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature0132212490959
   PubMed Web of Science ®Google Scholar
• McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neutrophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol. 2001;27(4):396–403. doi:10.1053/ejso.2001.113311417987
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi:10.1200/JCO.2010.30.503721483002
   PubMed Web of Science ®Google Scholar
• Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 2011;31(9):2995–2998.21868550
   PubMed Web of Science ®Google Scholar
• Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16(3):614–622. doi:10.1245/s10434-008-0267-619130139
   PubMed Web of Science ®Google Scholar
• Aizawa M, Gotohda N, Takahashi S, Konishi M, Kinoshita T. Predictive value of baseline neutrophil/lymphocyte ratio for T4 disease in wall-penetrating gastric cancer. World J Surg. 2011;35(12):2717–2722. doi:10.1007/s00268-011-1269-221913135
   PubMed Web of Science ®Google Scholar
• Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141–151. doi:10.1097/SLA.0b013e3181a77e5919561458
   PubMed Web of Science ®Google Scholar
• Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197–203. doi:10.1016/j.amjsurg.2009.08.04120122680
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320. doi:10.1186/s12885-016-2352-827198767
   PubMed Web of Science ®Google Scholar
• Rossi L, Santoni M, Crabb SJ, et al. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015;22(4):1377–1384. doi:10.1245/s10434-014-4097-425234022
   PubMed Web of Science ®Google Scholar
• Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol. 2015;22(2):670–676. doi:10.1245/s10434-014-4021-y25155401
   PubMed Web of Science ®Google Scholar
• Stephen BE, Compton C. The American Joint Committee on cancer: the 7th edition of the AJCC. Ann Surg Oncol. 2010;17:1471–1474. doi:10.1245/s10434-010-0985-420180029
   PubMed Web of Science ®Google Scholar
• SobinLH, WittekindC. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 7th ed. NewYork: Wiley-Liss; 2011: 164–173.
   Google Scholar
• Hatoum HA, Jamali FR, El-Saghir NS, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Indian J Surg Oncol. 2010;1(4):305–312. doi:10.1007/s13193-011-0062-x22695879
   PubMedGoogle Scholar
• Van Belle V, Van Calster B, Wildiers H, Van Huffel S, Neven P. Lymph node ratio better predicts disease-free survival in node-positive breast cancer than the number of positive lymph nodes. J Clin Oncol. 2009;27(30):e150–e151; author reply e152. doi:10.1200/JCO.2009.24.0044
   Web of Science ®Google Scholar
• Ibrahim EM, Elkhodary TR, Zekri JM, et al. Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia. Asia Pac J Clin Oncol. 2010;6(2):130–137. doi:10.1111/j.1743-7563.2010.01288.x20565426
   PubMed Web of Science ®Google Scholar
• Yang J, Long Q, Li H, Lv Q, Tan Q, Yang X. The value of positive lymph nodes ratio combined with negative lymph node count in prediction of breast cancer survival. J Thorac Dis. 2017;9(6):1531–1537. doi:10.21037/jtd.2017.05.3028740666
   PubMed Web of Science ®Google Scholar
• Truong PT, Vinh-Hung V, Cserni G, Woodward WA, Tai P, Vlastos G; Member of the International Nodal Ratio Working Group. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer. 2008;44(12):1670–1677. doi:10.1016/j.ejca.2008.05.01118595686
   PubMed Web of Science ®Google Scholar
• Keam B, Im SA, Kim HJ, et al. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2009;116(1):153–160. doi:10.1007/s10549-008-0160-918787948
   PubMed Web of Science ®Google Scholar
• Cho DH, Bae SY, You JY, et al. Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer. Kaohsiung J Med Sci. 2018;34(6):341–347. doi:10.1016/j.kjms.2017.12.01529747778
   PubMed Web of Science ®Google Scholar
• Li X, Tan Q, Li H, Yang X. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis. J Surg Oncol. 2021;123(1):89–95. doi:10.1002/jso.2625233047336
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Tsai J, Bertoni D, Hernandez-Boussard T, Telli ML, Wapnir IL. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol. 2016;23(10):3310–3316. doi:10.1245/s10434-016-5319-827401442
   PubMed Web of Science ®Google Scholar
• Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004;70(3):225–230. doi:10.1016/j.radonc.2003.10.01515064006
   PubMed Web of Science ®Google Scholar
• Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr. Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1788 patients with long-term follow-up. J Am Coll Surg. 2010;210(5):797–805.e1, 805–807. doi:10.1016/j.jamcollsurg.2010.02.045
   PubMed Web of Science ®Google Scholar
• N.C.C.N. (NCCN). Clinical practice guidelines in oncology. v.1.2012. Breast Cancer; 2012. Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 720, 2021.
   Google Scholar
• Marin Hernandez C, Pinero Madrona A, Gil Vazquez PJ, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol. 2018;20(4):476–483. doi:10.1007/s12094-017-1732-028785911
   PubMed Web of Science ®Google Scholar
• Xu J, Ni C, Ma C, et al. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol. 2017;19(8):989–996. doi:10.1007/s12094-017-1630-528247194
   PubMed Web of Science ®Google Scholar
• McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999;134(12):1325–1331; discussion 1331–1332. doi:10.1001/archsurg.134.12.1325
   PubMedGoogle Scholar
• Jablonska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jablonski J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp. 2001;49(1):63–69.
   PubMed Web of Science ®Google Scholar
• Wang X, Yin Z, Wang D, et al. Greater negative lymph node count predicts favorable survival of patients with breast cancer in the setting of neoadjuvant chemotherapy and mastectomy. Future Oncol. 2019;15(32):3701–3709. doi:10.2217/fon-2019-043931538504
   PubMed Web of Science ®Google Scholar